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Second sodium pumpClinical and experimental data show an increase in sodium reabsorption on the proximal tubule (PT) in
essential hypertension. It is well known that there is a link between essential hypertension and renal
angiotensin II (Ang II). The present study was designed to examine ouabain-insensitive Na+-ATPase activity
and its regulation by Ang II in spontaneously hypertensive rats (SHR). We observed that Na+-ATPase
activitywasenhanced in14-week-oldbut not in6-week-old SHR. The additionofAng II from10−12 to 10−6mol/L
decreased the enzyme activity in SHR to a level similar to that obtained in WKY. The Ang II inhibitory effect
was completely reversed by a speciﬁc antagonist of AT2 receptor, PD123319 (10
−8 mol/L) indicating that a
system leading to activation of the enzyme in SHR is inhibited by AT2-mediated Ang II. Treatment of SHR
with losartan for 10 weeks (weeks 4–14) prevents the increase in Na+-ATPase activity observed in 14-week-
old SHR. These results indicate a correlation between AT1 receptor activation in SHR and increased ouabain-
insensitive Na+-ATPase activity. Our results open new possibilities towards our understanding of the
pathophysiological mechanisms involved in the increased sodium reabsorption in PT found in essential
hypertension.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The kidneys play a crucial role in the long-term regulation of
systemic blood pressure (BP) [1–3].This role is strictly correlated to
the ability of the kidneys to ﬁne tune the level of the sodium excretion
at different BP levels [4,5]. According to Guyton's hypothesis,
whenever arterial blood pressure is elevated an increase in natriuresis
pressure occurs and, consequently, in renal sodium excretion [6,7].
This hypothesis predicts that the mechanism that resets this relation-
ship towards higher pressure leads to hypertension [8].
The renal mechanisms of Na+ transport are themain determinants
of urinary Na+ excretion, constituting the primary regulators of
extracellular ﬂuid volume and, therefore, contributing to the main-
tenance of BP [9]. The observation that patients with essential
hypertension as well as spontaneously hypertensive rats (SHR)
show increased sodium reabsorption on the proximal tubule (PT)
indicates that this segment plays an important role during the genesis
of the hypertension [8,10–13]. Furthermore, before the onset of+55 21 2280 8193.
).
nt of this work.
ll rights reserved.hypertension, SHR already show increased sodium and water
reabsorption [11], and the PT has been implicated in this sodium
retention [13,14].
The basolateral sodium transport is one of the limiting steps to PT
sodium reabsorption [15,16]. Two sodium pumps have been described
in this renal segment: the classic (Na++K+)ATPase and the ouabain-
insensitive, furosemide-sensitive Na+-ATPase [15,17,18]. It was shown
that in SHR the (Na++K+)ATPase activity in PT is increased in 5-
week-old rats but is not changed in animals more than 12 weeks
of age [19,20]. On the other hand, it has been observed that the
increased sodium reabsorption in PT cells is maintained even in adult
animals and the transporter involved in this process is still to be
determined.
SHR has been used as a model of essential hypertension [21]. It is
well known that there is a link between essential hypertension and
the rennin/angiotensin system (RAS) [22]. It is well recognized that
PT function is regulated by both circulating and locally formed
angiotensin II (Ang II) [23]. Matsushima et al. [24] observed that the
content of Ang II in the renal cortex is increased in 14-week-old SHR.
Our group showed that the PT Na+-ATPase is the target for some
peptides such as Ang II [25–27]. Then, the selective modulation of
Na+-ATPase by Ang II may be an important mechanism of extra-
cellular ﬂuid volume control and, consequently, of arterial blood
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the activity of this enzyme would be changed in hypertension.
Therefore, the present studywas designed to examine the role of Na+-
ATPase in SHR and its regulation by Ang II.
2. Materials and methods
2.1. Materials
Adenosine triphosphate (magnesium salt; Mg-ATP), ouabain,
furosemide, sodium chloride, potassium chloride, magnesium
chloride, ethylenediaminetetracetic acid (EDTA), N-2-hydroxyethyl-
piperazine N'-2-ethanesulfonic acid (HEPES), (trishydroxymethyl)-
aminomethane (Tris), histone, bovine serum albumin (BSA),
phenylmethylsulfonyl ﬂuoride (PMSF), PD123319 and guanosine 5-
[β-thio]diphosphate (GDPβS) were purchased from Sigma Aldrich
Company (St. Louis, MO). Sucrose and choline chloride were from
Merck (Darmstadt, Germany). The AT1 receptor selective antagonist,
losartan, was obtained from Medley S.A. (São Paulo, Brazil). [32Pi]Pi
was obtained from the Brazilian Institute of Energetic and Nuclear
Research, São Paulo, Brazil. [γ-32Pi]ATP was synthesized according to
the procedures described by Maia et al. [28]. All other reagents were
of the highest purity available.
2.2. Animals
All the animal procedures were conducted in accordance with the
National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Ethics
Committee of Federal University of Rio de Janeiro (number IBCCF004).
Adult maleWistar Kyoto (WKY) and Spontaneously Hypertensive Rats
(SHR) aged 6 or 14 weeks were purchased from Centro de
Desenvolvimento de Modelos Experimentais, Escola Paulista de
Medicina, São Paulo, Brazil. The animals were reared four per cage
with free access to food and water in a room maintained at 25±1 °C,
55±5% humiditywith a 12-h light–dark cycle. In agreementwith data
from other authors [29–31], we observed that 6-week-old SHR did not
develop hypertension, while at 14 weeks, hypertension is already
established.
2.3. Treatment
The SHR were randomly divided into four groups according to
the treatment: Group 1, WKY rats, used as normotensive controls,
received vehicle (water) for 10 weeks (WKY-V); Group 2, SHR
treated with losartan for 6 weeks and then vehicle (water) for
4 weeks (SHR-L up to 10 weeks old); Group 3, SHR treated with
losartan for 10 weeks (SHR-L up to 14 weeks old); and Group 4, SHR
treated only with vehicle (water, SHR-V). The treatments were
administered by gavage once daily and body weight was measured
daily for adjustment of the losartan dose to 30 mg/kg per day.
Arterial blood pressure was measured weekly by the tail-cuff
compression method (Non-invasive Blood Pressure Instrument LE
5001, Panlab, Barcelona, Spain) for the duration of the treatment.
After the treatment the animals were anesthetized with 100 mg/kg
ketamine and 20 mg/kg xylazine and then the kidneys were
removed to prepare the microsomal fraction of the kidney cortex as
described below.
2.4. Non-invasive BP measurement
Twenty male rats were used for the non-invasive blood pressure
measurements using a Letica LE 5001 instrument (Barcelona, Spain).
The tail-cuff method was carried out as previously reported [32]. For
accurate blood pressure measurements, the animals were kept in a
warm environment (30–32 °C) for at least 30 min until arterial tailpulsations were detected. Three consecutive, consistent readings of
the systolic blood pressure (SBP), diastolic blood pressure (DBP),
mean blood pressure (MBP) and heart rate (HR) were taken in each
individual, and the values were averaged.
2.5. Preparation of the microsomal fraction
The microsomal fraction was obtained using a previous method
with a few modiﬁcations [33]. Brieﬂy, the kidneys were removed and
maintained in cold solution containing (mmol/L): sucrose 250,
HEPES–Tris (pH 7.6) 10, EDTA 2 and PMSF 1. Thin slices of the cortex
(cortex corticis) were removed with a Stadie Riggs microtome using a
scalpel. After dissection, the slices were homogenized in the same cold
solution using a Teﬂon and glass homogenizer. The homogenate was
centrifuged at 3000 rpm for 10min at 4 °C in a Hitachi-Himac SCR-20B
centrifuge using a RPR 20.2 rotor. The supernatant was centrifuged at
6000 rpm for 20 min at 4 °C using the same centrifuge and rotor. The
new supernatant was ultracentrifuged at 60,000 rpm for 1 h at 4 °C in
a Beckman XL100 centrifuge using a type 70 Ti rotor. The ﬁnal pellet
containing amicrosomal fractionwas re-suspended and homogenized
in 250 mmol/L sucrose to a ﬁnal concentration of 2–3 mg of protein/
mL. This preparation was stored at−4 °C and protein concentrations
were determined by the Folin phenol method [34] using bovine serum
albumin (BSA) as standard.
2.6. Measurements of ATPase activity
The ATPase activity was measured according to the method
described by Grubmeyer and Penefsky [35]. The composition of the
assay medium for the measurement of ATPase activity (0.1 ml) was:
2 mmol/L MgCl2, 20 mmol/L HEPES–Tris (pH 7.0), 4 mmol/L ATP (as
ATP-Mg), and 120 mmol/L NaCl. [γ-32P]ATP was added to a speciﬁc
activity of 3000 cpm/nmol. The Na+-ATPase activity was determined
from the difference between [32P]Pi released in the absence and in the
presence of 2mM furosemide (an Na+-ATPase speciﬁc inhibitor), both
in the presence of 1 mM ouabain (an (Na++K+)ATPase speciﬁc
inhibitor) and in the absence of KCl. For measurement of (Na++K+)
ATPase activity, 30 mmol/L KCl was added and the activity was
determined from the difference between [32P]Pi released in the
absence and in the presence of 1 mM ouabain. In the absence of NaCl
or KCl, choline chloride was added to maintain a constant ionic
strength. The reaction was started by the addition of the microsomal
fraction to the assay medium to a ﬁnal protein concentration of 0.3–
0.5 mg/mL at 37 °C and stopped after 10 min by the addition of
0.1 mol/L HCl-activated charcoal. The [32P]Pi released was measured
in an aliquot of the supernatant obtained after centrifugation of the
samples for 5 min at 2000 rpm in a clinical centrifuge. The
radioactivity was quantiﬁed by liquid scintillation counting (Packard
Tri-Carb 2100 TR). Spontaneous hydrolysis of [γ-32P]ATP was
measured simultaneously in tubes to which protein was added after
the acid.
2.7. Kinetic parameters
The kinetic parameters were derived from the experimental data
by using the statistical curve-ﬁtting package SigmaPlot® (San Jose, CA,
USA). This program calculates the kinetic parameters using a non-
linear regression method. The interpolation is automatically obtained
by derivation of the Michaelis–Menten equation. The non-linear
regression coefﬁcient obtained was always higher than 0.99 under all
conditions.
2.8. Statistical analysis
The means were compared by one-way analysis of variance
(ANOVA) taking into account the treatment of the experimental
Fig. 2. Differences in kinetic parameters of Na+-ATPase in the PT between SHR and
WKY rats. Na+ concentration dependence of ATPase activity in PT of 6-week-old (A) or
14-week-old (B) SHR (open symbols) and WKY rats (closed symbols) in the presence
of 1 mmol/L ouabain and in the absence of KCl. ATPase activity was measured as
described in the Materials and methods section and the indicated Na+ concentrations
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multiple comparative Bonferroni test. Then values correspond to the
results obtained from different microsomal fraction preparations of
different animals.
3. Results
3.1. Sodium pump activities in SHR and WKY
In the ﬁrst experimental group we measured ouabain-insensitive
Na+-ATPase and (Na++K+)ATPase activities in 6- or 14-week-old
SHR and in age-matched WKY used as controls. The Na+-ATPase
activity was not different in 6-week-old SHR (Fig. 1A) but it was
signiﬁcantly enhanced in 14-week-old SHR compared with the
controls (Fig. 1B). On the other hand, (Na++K+)ATPase activity was
increased in 6-week-old SHR (Fig. 1A) but was not different in 14-
week-old SHR (Fig. 1B). It is important to note that the ATPase activity
in the absence of Na+was not different in both 6 and 14-week-old SHR
(data not shown). Our results show that ouabain-insensitive Na+-
ATPase and (Na++K+)ATPase activities are modulated at different
ages of SHR during the development of hypertension.
Fig. 2 shows the Na+ dependence of the hydrolytic activity of
ouabain-insensitive Na+-ATPase in the presence of 1 mmol/L ouabain
and in the absence of K+, in 6- and 14-week-old WKY and SHR.
Under such conditions, (Na++K+)ATPase is completely inhibited.
The increase in Na+ concentration enhanced the ATPase activity in
a dose-dependent manner in both SHR and WKY. The Na+
concentration that promoted half-maximal stimulation (K0.5) of
Na+-ATPase and the maximal rate (Vmax) in 6-week-old WKY
was 2.5±1.4 mmol/L and 44.7±2.3 nmol Pi mg−1 min−1 (Fig. 2A).
Although the Vmax was not different (Vmax=37.8±2.3 nmol Pi
mg−1 min−1) in age-matched SHR, the K0.5 for Na+ decreased
18 times to 0.15±0.06 mmol/L. On the other hand, in 14-week-old
SHR, differences in both parameters, Vmax and K0.5, was observed
(Fig. 2B). The K0.5 for Na+ decreased from 10.7±2.8 mmol/L (WKY)
to 0.38±0.12 mmol/L and Vmax increased from 24.7±2.2 (WKY) to
51.1±2.7 nmol Pi mg−1 min−1. The K0.5 for Na+ found in 14-week-
old WKY agrees with the value obtained by other authors in isolatedFig. 1. Differences in PT ATPase activity between SHR andWKY rats. ATPase activity was
measured as described in the Materials and methods section. (A) (Na++K+) ATPase
and Na+-ATPase activity in 6-week-oldWKY (black bars) and SHR (gray bars) (n=10).
(B) (Na++K+) ATPase and Na+-ATPase activity in 14-week-old WKY (black bars) and
SHR (gray bars) (n=10). Results are expressed as mean±SE. ⁎Statistically signiﬁcant
when compared to respective controls (p b0.05).
(as NaCl). (C) The kinetic parameters were calculated using the following equation:
v=Vmax[S]/K0.5+[S] for the 6- and 14-week-oldWKYand SHR rats. The data (mean±SE)
correspond to the difference between parallel assays performed in the absence or in
the presence of each Na+ concentration. All experiments were done in duplicate
(n=8).basolateral membrane (BLM) of proximal tubule [36,37]. The Na+-
ATPase activity in 6-week-old WKY is higher than the activity in
14-week-old WKY, but in SHR the activity is maintained in 14-
week-old animals.
3.2. Ang II interacts with different receptors in SHR and WKY
In a previous paper we observed that Ang II modulates ouabain-
insensitive Na+-ATPase activity in isolated basolateral membrane of
the pig PT: the AT1 receptor increases the enzyme activity [25], and the
AT2 receptor inhibits it [38]. In the next experimental group we
decided to investigate if the effect of exogenous addition of Ang II on
the ouabain-insensitive Na+-ATPase activity in 6- (Fig. 3A) and 14-
week-old (Fig. 3B) SHR could be changed. To test the effect of Ang II,
the microsomal fraction was previously incubated with Ang II, at the
concentrations indicated, for 30 min, and then the enzyme activity
assays were carried out. This procedure was carried out every timewe
tested for the effect of Ang II. The increase in Ang II concentration from
10−12 to 10−6 mol/L increased the enzyme activity in 6- and 14-
week-old WKY in a similar way to that observed by our group in
isolated BLM of PT cells. The same behavior of the effect of Ang II was
Fig. 3.Modulation of Na+-ATPase activity by Ang II in 6- and 14-week-old SHR andWKY
rats. Na+-ATPase activity was measured as described in the Materials and methods
section. The Ang II concentration ranged from 10−12 mol/L to 10−6 mol/L. (A) The Ang
II effect on 6-week-oldWKY (closed symbols) and SHR (open symbols) rats (n=7). (B)
Ang II effect on 14-week-old WKY (closed symbols) and SHR (open symbols) rats
(n=5). Results are expressed as percentage of the control (mean±SE). ⁎Statistically
signiﬁcant when compared to respective controls in the absence of Ang II (p b0.05).
Dashed line represents the control value of the SHR and WKY taken as 100%.
Fig. 4. Identiﬁcation of the angiotensin receptor involved in the Ang II effect on adult SHR
Na+-ATPase. ATPase activity was measured as described in the Materials and methods
section. (A) Effect of the AT1 antagonist, losartan, and AT2 antagonist, PD123319, on Ang
II modulation of Na+-ATPase activity in 14-week-old WKY (black bars) and SHR (gray
bars) rats (n=9). (B) Effect of the G protein inhibitor, GDPβS, on the Ang II effect
(n=5). Results are expressed as % of the control (mean±SE). ⁎Statistically signiﬁcant
when compared to the respective controls in the absence of Ang II or GDPβS (p b0.05).
Dashed line represents the control value of SHR and WKY taken as 100%.
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old SHR, an inhibitory effect of Ang II on the enzyme activity was
observed, which is contrary to that observed in age-matched WKY
(Fig. 3B). The maximal effect under all conditions was obtained at a
concentration of 10−10 mol/L. Exogenous Ang II, in 14-week-old SHR,
decreased the ouabain-insensitive Na+-ATPase activity to a level
similar that obtained in WKY in the absence of Ang II. These results
show that there is an anomaly effect of Ang II on ouabain-insensitive
Na+-ATPase activity that is a consequence of something that happens
between birth and 14 weeks in SHR.
In order to identify which receptor could be involved in the effect
of exogenous Ang II on the ouabain-insensitive Na+-ATPase activity in
14-week-old SHR and WKY, we used speciﬁc antagonists for AT1 and
AT2 receptors, losartan and 7PD123319, respectively (Fig. 4A). The
stimulatory effect of 10−9 mol/L Ang II on Na+-ATPase activity in
WKY was completely reversed by 10−6 mol/L losartan but it was not
modiﬁed by 10−8 mol/L PD123319. On the other hand, in SHR, the
inhibitory effect of exogenous Ang II was completely reversed by
10−8 mol/L PD123319 but it was notmodiﬁed by 10−6mol/L losartan.
The addition of 10−8 mol/L PD123319 or 10−6 mol/L losartan alone
did not change the enzyme activity in both WKY and SHR (data not
shown). These results indicate that themodulatory effect of exogenous
Ang II on Na+-ATPase activity is mediated by different receptors, AT1
and AT2, in 14-week-old WKY and SHR, respectively.
The Ang II receptors, AT1 and AT2, have seven transmembrane
domains and belong to the family of G protein-coupled receptors
(GPCR) [39,40]. Fig. 4A shows that the effects of Ang II on the enzyme
activity in 14-week-old WKY and SHR were completely abolished by
10−8 mol/L GDPβS, a speciﬁc inhibitor of trimeric G protein. This
scenario indicates that in hypertensive animals, activation of some
system occurs leading to the increase in enzyme activity which is
inhibited by addition of Ang II activating AT2 receptor.3.3. AT1 receptor is responsible for activation of the ouabain-insensitive
Na+-ATPase in adult SHR
It is known that the level of AT1 receptor is increased in 4-week-old
SHR but it is not changed in adult animals (14–16 weeks old) [41].
Therefore, it is possible to imagine that changes in this period could be
responsible for changes in sodium transport in adult animals. To
address this question, we treated 4-week-old SHR or age-matched
WKY daily with 30 mg/kg losartan by gavage as described in the
Materials and methods section (Fig. 5). After the treatment, the
microsomal fraction of the kidney cortex was prepared separately
from each animal in different groups and then the Na+-ATPase
activity assay was carried out.
Treatment of SHR with losartan for 10 weeks (weeks 4–14) or
treated with losartan for 6 weeks (weeks 4–10) and vehicle for a
further 4 wks (weeks 10–14) avoided the development of hyperten-
sion (Fig. 5A) and the increase in ouabain-insensitive Na+-ATPase
activity (Fig. 5B) observed in 14-week-old SHR. Under these condi-
tions, ouabain-insensitive Na+-ATPase activity was decreased by 50%
compared to age-matched WKY-V. Treatment of SHR with vehicle for
the same period of time did not change the enzyme activity and mean
arterial blood pressure (MAP) when compared to untreated SHR.
(Na++K+)ATPase activity in 14-week-old animals was not changed
under any of the conditions tested (data not shown). These results
indicate a clear correlation between AT1 receptor activity and
ouabain-insensitive Na+-ATPase activation of kidney cortex.
In the last experimental group, we tested whether treatment of
the SHR with losartan avoids the changes in kinetic parameters of
the Na+-ATPase (Fig. 6). SHR were treated with losartan (SHR-L) or
treated with vehicle (water, SHR-V) for 10 weeks. WKY treated with
Fig. 5. The AT1 receptor is involved in the activation of Na+-ATPase in adult SHR.
Animals were treated as described in the Materials and methods section. WKY-V, WKY
rats received vehicle (water) for 10 weeks; SHR-V, SHR treated only with vehicle
(water); SHR-L up to 10 weeks old, SHR treated with losartan for 6 weeks and then
vehicle (water) for 4 weeks; and SHR-L up to 14 weeks old, SHR treated with losartan
for 10 weeks (n=6/group). (A) mean arterial blood pressure (MAP) measured weekly
in all groups; (B) renal cortex Na+-ATPase activity in the same conditions described in
panel A. Results are expressed as % of the control (mean±SE). ⁎Statistically signiﬁcant
when compared to the respective controls (p b0.05).
Fig. 6. Kinetic parameters of Na+-ATPase after losartan treatment. (A) Na+ concentra-
tion dependence of ATPase activity in 14-week-old WKY-V (closed circles, WKY treated
only with water), SHR-V (open circles, SHR treated only with water) and SHR-L (open
triangles, SHR treated with losartan for 10 weeks). All experiments were carried out in
the presence of 1 mmol/L ouabain and in the absence of KCl. ATPase activity was
measured as described in the Materials and methods section and at the indicated Na+
concentrations (as NaCl). (B) The kinetic parameters were calculated using the
following equation: v=Vmax[S]/K0.5+[S]. The data (mean±SE) correspond to the
difference between parallel assays performed in the absence or in the presence of each
Na+ concentration. All experiments were done in duplicate (n=8). ⁎Statistically
signiﬁcant when compared to WKY-V and #statistically signiﬁcant when compared to
SHR-V (p b0.05).
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treatment avoided the decrease in K0.5 for Na+ observed in SHR.
Furthermore, under these conditions losartan decreased Vmax even
when compared to WKY-V (in Fig. 6B).
4. Discussion
Our study shows for the ﬁrst time that ouabain-insensitive Na+-
ATPase activity is activated in adult spontaneously hypertensive rats.
Contrary to (Na++K+)ATPase, ouabain-insensitive Na+-ATPase
activity is increased in adult SHR when hypertension is already
established. The activation of the ouabain-insensitive Na+-ATPase in
SHR is correlated to AT1 receptor activity. Thus, we hypothesize that
the increase in expression of AT1 receptor expression in young animals
(4 weeks old), observed in other studies, promotes modiﬁcations in
the adult phase that lead to changes in ouabain-insensitive Na+-
ATPase activity and, consequently, in proximal tubule sodium
reabsorption.
The link between Na+-stimulated ATPase activity and proximal
tubule Na+ transport has been demonstrated by several authors [42–
45]. Furthermore, it has been proposed that ouabain-insensitive Na+-
ATPase is involved in ﬁne tuning, whereas (Na++K+)ATPase is
responsible for most of the Na+ reabsorption in the PT. In this way, any
change in ouabain-insensitive Na+-ATPase leads to signiﬁcant
changes in sodium reabsorption in proximal tubule cells as those
observed in SHR. The possible effect of furosemide on other ATPases or
on Na+/K+/2Cl− cotransporter can be ruled out as discussed in a
previous study [46].
The increase in ouabain-insensitive Na+-ATPase activity observed
in adult SHR is a consequence of the changes in both Vmax and
apparent afﬁnity for Na+. Based on the intracellular Na+ concentra-
tion, it is plausible to postulate that the Na+-ATPase is working at
almost maximal rate in both 6- and 14-week-old SHR. This result ﬁtsvery well with the abnormal increase in proximal tubule sodium
reabsorption observed in SHR [11–14] or primary hypertensive
patients [8,10] indicating the involvement of this enzyme, at least in
part, in this process. The role of this enzyme in hypertensive animal
models was also shown in a recent paper by Beltowski and coworkes
[47]. The authors showed that abnormal regulation of PT ouabain-
insensitive Na+-ATPase activity is involved in hypertension associated
with the metabolic syndrome.
It was shown that AT1 receptor interacts with (Na++K+)ATPase
through arrestins, which could lead to changes in the enzyme activity
[48]. However, this hypothesis is unlikely in the modulation of
ouabain-insensitive Na+-ATPase activity by the AT1-mediated Ang II
effect because we showed that the Ang II effect is completely reversed
by speciﬁc inhibitors of the PI-PLC/PKC pathway and by GDPβS
[25–27,38,40].
Here we have shown that the increase in Na+-ATPase activity of
kidney cortex is a consequence of AT1 receptor activity because
losartan treatment avoids the increase in enzyme activity. It has been
shown that the contribution of the PT in essential hypertension is
independent of age and salt-induced variations in renal hemody-
namics [49]. The changes in sodium reabsorption in PT could be due to
acquired renal tubular defects and/or molecular alterations. Thus, it is
possible to postulate that the increase in AT1 receptor expression in
young SHR leads to some modiﬁcations in adult SHR responsible for
the increase in PT Na+-ATPase activity.
The ﬁnal effect of Ang II on PT Na+-ATPase activity is a
consequence of the action of this peptide in two receptors: AT1 and
AT2 [25,38]. Usually, the level of the AT2 receptor is lower than the AT1
receptor and the ﬁnal effect of Ang II observed is that mediated by the
AT1 receptor. We showed in a previous paper that when AT1 receptor
is blocked by losartan Ang II inhibits the Na+-ATPase of pig proximal
tubule in a PD123319-sensitive way [25,38]. This result agrees with
the proposed role of the AT2 receptor in counteracting the AT1
receptor to achieve hydroelectrolytic balance in normotensive
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the addition of exogenous Ang II could work as a preferential agonist
of AT2 receptor, even when the expression of this receptor is
decreased. This hypothesis could explain the observation that
exogenous Ang II inhibited the ouabain-insensitive Na+-ATPase
activity in SHR through AT2 receptor. A possible increase in expression
of AT2 receptor in SHR can be ruled out because the observation that
the expression of AT2 receptor in mesenteric artery is decreased in
SHR [50].
The precise functional role of the renal AT2 receptor is so far poorly
deﬁned, especially in the kidney. Evidence accumulated in the last few
years suggests that the major function of AT2 receptors is related to
functional antagonism of the vasoconstrictor action of AT1 receptors.
Our results agree with recent observations that the AT2 receptor
represents a counter-regulatory mechanism of kidney protection in a
5/6 uninephrectomy model [51,52]. Further investigations are
necessary to elucidate the role of AT2 receptor in the genesis of the
primary hypertension.
Clinical and experimental data conﬁrm the critical role of the
kidneys in essential hypertension. This mechanism seems to be
associated with the establishment of essential hypertension and it
could be caused, at least in part, by the high level of Ang II in the renal
cortex. We observed a correlation between Na+-ATPase activity and
AT1 receptor activation with the establishment of essential hyperten-
sion. Furthermore, our ﬁndings indicate that Na+-ATPase is a key
target during the development of hypertension. Our results open up
new possibilities in our understanding of the pathophysiological
mechanisms involved in the increased sodium reabsorption in PT
found in essential hypertension.
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